Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy

Documenti analoghi

• Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
  di: Yiling Ye, et al.
  Pubblicazione: (2025)
• Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission
  di: Xi Jia, et al.
  Pubblicazione: (2024)
• FLT‐3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation
  di: Song Xue, et al.
  Pubblicazione: (2024)
• Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemia
  di: Brandon J. Aubrey, et al.
  Pubblicazione: (2026)
• Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax
  di: Stefano Cordella, et al.
  Pubblicazione: (2024)